VTRS · Viatris Inc.
$13.442026-05-17Sector: Healthcare; Industry: Drug Manufacturers - Specialty & Generic; Sub-Industry: Pharmaceuticals
Intrinsic Value Range Comparison · Mulya.ai
Base · active
$0
-146.6% vs market
Mulya.ai vs Analyst IV Comparison?
Mulya.ai IV range ($0 · $10) Analysts Range ($12 · $18) Fundamentals · historical + forward · baseitalics = DCF projection
| Period | Revenue | Rev Gr ? | Ops M% ? | Tax Rate ? | NOPAT ? | Reinvest ? | FCFF ? | WACC% ? | PV FCFF ? | ROIC ? | Inv. Cap ? | EPS ? | P/E |
|---|
| 2021.Q4 | $17.9B | — | -0.2% | 0.0% | −$65MM | $2.6B | $2.5B | 19.9% | — | -0.2% | $42.7B | $-1.10 | — |
| 2022.Q4 | $16.3B | -9.1% | 9.9% | 26.1% | $1.2B | $1.7B | $2.9B | 7.2% | — | 2.9% | $38.9B | $1.80 | — |
| 2023.Q4 | $15.4B | -5.1% | 5.0% | 45.0% | $421MM | $1.2B | $1.7B | 6.7% | — | 1.1% | $37.5B | $0.05 | — |
| 2024.Q4 | $14.7B | -4.5% | 0.1% | 0.0% | $10MM | $2.5B | $2.5B | 15.0% | — | 0.0% | $31.7B | $-0.55 | — |
| 2025.Q4 | $14.3B | -3.0% | -18.6% | 4.1% | −$2.6B | −$201MM | −$2.8B | 11.7% | — | -8.6% | $27.8B | $-3.05 | — |
| italics below = DCF projection · 10yr Rev CAGR: 3.2% |
| 2026.Q4 | $14.6B | +2.3% | 0.6% | 5.7% | $82MM | −$1.1B | −$1.0B | 11.1% | −$924MM | 0.3% | $28.9B | $0.07 | 192.0 |
| 2027.Q4 | $15.0B | +2.5% | 0.6% | 7.3% | $85MM | −$986MM | −$901MM | 10.9% | −$731MM | 0.3% | $29.9B | $0.07 | 192.0 |
| 2028.Q4 | $15.4B | +2.7% | 0.6% | 8.9% | $86MM | −$909MM | −$823MM | 10.6% | −$604MM | 0.3% | $30.8B | $0.07 | 192.0 |
| 2029.Q4 | $15.8B | +2.9% | 0.6% | 10.5% | $87MM | $0MM | $87MM | 10.4% | $58MM | 0.3% | $30.8B | $0.08 | 168.0 |
| 2030.Q4 | $16.3B | +3.1% | 0.6% | 12.1% | $88MM | $0MM | $88MM | 10.1% | $53MM | 0.3% | $30.8B | $0.08 | 168.0 |
|
| Term. Yr+ | $20.4B | 4.1% | 25.6% | 20.0% | $4.2B | −$2.0B | $2.2B | 8.6% | $18.7B | 8.6% | — | — | — |
Active scenario IV: $0 (-146.6% vs market)